"Liver Cirrhosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Descriptor ID |
D008103
|
| MeSH Number(s) |
C06.552.630
|
| Concept/Terms |
Liver Cirrhosis- Liver Cirrhosis
- Cirrhosis, Liver
- Cirrhoses, Liver
- Liver Cirrhoses
- Hepatic Cirrhosis
- Cirrhoses, Hepatic
- Cirrhosis, Hepatic
- Hepatic Cirrhoses
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis".
This graph shows the total number of publications written about "Liver Cirrhosis" by people in this website by year, and whether "Liver Cirrhosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 3 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 5 | 0 | 5 |
| 2009 | 5 | 3 | 8 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 1 | 4 |
| 2012 | 4 | 2 | 6 |
| 2013 | 4 | 2 | 6 |
| 2014 | 6 | 2 | 8 |
| 2015 | 8 | 3 | 11 |
| 2016 | 14 | 4 | 18 |
| 2017 | 12 | 2 | 14 |
| 2018 | 6 | 3 | 9 |
| 2019 | 13 | 3 | 16 |
| 2020 | 4 | 8 | 12 |
| 2021 | 4 | 15 | 19 |
| 2022 | 0 | 9 | 9 |
| 2023 | 2 | 15 | 17 |
| 2024 | 4 | 6 | 10 |
| 2025 | 5 | 5 | 10 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis" by people in Profiles.
-
Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age. Dig Liver Dis. 2026 07; 58(7):935-942.
-
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review. Liver Int. 2026 05; 46(5):e70608.
-
Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators. PLoS One. 2026; 21(3):e0328952.
-
Trichosanthes kirilowii extract alleviated liver fibrosis and acute myocardial infarction by inhibiting VCAN to restrain monocyte senescence: Insights from bioinformatic analyses and experimental validation. Phytomedicine. 2026 Apr; 153:157941.
-
Assessing Predictive Performance of Fibrosis-4 Index in Settings With Lower Prevalence of Liver Fibrosis. Clin Gastroenterol Hepatol. 2026 Sep; 24(9):2623-2625.
-
Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries. Liver Int. 2025 12; 45(12):e70390.
-
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1089-1099.
-
Serum Proteomic Profile Based on the TGF-ß Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver Int. 2025 10; 45(10):e70325.
-
Lateral Versus Midline: A Retrospective Review of Paracentesis Site Location and Risk of Hemorrhagic Complication. Crit Care Med. 2025 Dec 01; 53(12):e2698-e2705.
-
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26; 392(24):2413-2424.